Background: Treatment of non-small cell lung cancer (NSCLC) remains challenging; 5-year survival is as low as 24% for resectable disease. However, the outlook for stage IA NSCLC is favorable, with 5-year survival exceeding 74% and with surgery often being curative. Despite this positive prognosis, low socioeconomic status has been shown to correlate with nonstandard treatment and worse overall survival specifically in stage IA. This study sought to examine income-based disparities in postsurgical survival which has yet to be discussed in the current literature.
Methods: The National Cancer Database was retrospectively queried from 2004 to 2017 to identify patients with pathological stage IA NSCLC following surgical resection; survival/patient characteristics were analyzed by income quartiles and eras (2004-2007, 2008-2012, and 2013-2017). Kaplan-Meier methods and multivariable Cox hazard modeling were used to estimate survival and construct hazard ratios, respectively.
Results: Inclusion criteria identified 138,219 patients. Overall, a stepwise decrease in 5-year survival was observed as income quartile decreased (Q4: 72.0%; Q3: 67.8%; Q2: 66.1%; Q1: 64.2%). Hazard modeling implicated income level as an independent predictor of mortality; patients of the lowest income quartile exhibited a hazard ratio of 1.26 (95% confidence interval 1.21-1.31; p < 0.001) relative to the highest. Although overall survival increased within each income quartile over consecutive eras, income-based survival disparities continued to be observed.
Conclusions: Lower-income patients with stage IA NSCLC display elevated mortality risk over 5 years than higher-income patients despite receiving potentially curative surgery, with income being an independent risk-factor. This difference may also be attributed to stacked risk-factors in lower-income patients.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1245/s10434-025-17107-0 | DOI Listing |
J Urol
March 2025
Division of Urologic Surgery, Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA.
Purpose: Cryoablation (CA) and partial nephrectomy (PN) are effective nephron-sparing treatments for small renal masses. While guidelines list thermal ablation as an option for tumors <3 cm, limited data compare PN and CA in larger tumors. We compared intermediate-term oncologic outcomes between PN and CA in renal masses >3 cm.
View Article and Find Full Text PDFAnn Surg Oncol
March 2025
Department of Cardiothoracic Surgery, Mayo Clinic Arizona, Phoenix, AZ, USA.
Background: Treatment of non-small cell lung cancer (NSCLC) remains challenging; 5-year survival is as low as 24% for resectable disease. However, the outlook for stage IA NSCLC is favorable, with 5-year survival exceeding 74% and with surgery often being curative. Despite this positive prognosis, low socioeconomic status has been shown to correlate with nonstandard treatment and worse overall survival specifically in stage IA.
View Article and Find Full Text PDFDig Dis Sci
March 2025
Department of Gastroenterology of Nara Medical University, 840 Shijo-cho, Kashihara, Nara, Japan.
Aim: The incidence of intrahepatic distant recurrence (IDR) of hepatocellular carcinoma (HCC) still remains high after radiofrequency ablation (RFA). However, serum alpha-fetoprotein (AFP) has insufficient screening power. This study aimed to identify risk factors for IDR in patients with post-RFA HCC.
View Article and Find Full Text PDFBreast Cancer Res Treat
March 2025
Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
Introduction: Outcome prediction research in early-onset breast cancer (EoBC) is limited. This study evaluated the predictive performance of NHS PREDICT v2.1 and developed two prediction models for 5-year and 10-year all-cause mortality in a cohort of EoBC patients in Alberta, Canada.
View Article and Find Full Text PDFAm J Gastroenterol
March 2025
Division of Gastroenterology, University of California, San Diego, La Jolla, California, USA.
Gastric premalignant conditions (GPMC) are common and include atrophic gastritis, gastric intestinal metaplasia, dysplasia, and certain gastric epithelial polyps. GPMC have an increased risk of progression to gastric adenocarcinoma. Gastric cancer (GC) in the United States represents an important cancer disparity because incidence rates are 2- to 13-fold greater in non-White individuals, particularly early-generation immigrants from regions of high GC incidence.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!